|Tel||+44 (0) 1865 612274|
- Transplantation Research Immunology Group (TRIG) Research Group
I am a senior postdoctoral researcher working in the Transplantation Research Immunology Group (TRIG). My research focuses on developing therapies that could prevent transplant rejection without the need for immunosupression.
Transplantation is currently the best treatment for the end-stage organ failure; however transplant recipients require life-long immunosuppression which is associated with significant side-effects.
My work focuses on immune cells with regulatory properties, mainly regulatory T cells (Treg) and the mechanisms of suppression utilized by these cells. Using a clinically relevant model of transplant rejection I am studying the ability of different human Treg subsets to mediate tolerance and the molecular pathways involved in this process.
By providing the data on the in vivo efficacy of ex vivo expanded human Treg, my research helped to inform the currently ongoing clinical study testing safety and efficacy of Treg cells in kidney transplant recipients.
Conversion to sirolimus in kidney transplant recipients with squamous cell cancer and changes in immune phenotype.
Carroll RP. et al, (2013), Nephrol Dial Transplant, 28, 462 - 465
Multiple unit pooled umbilical cord blood is a viable source of therapeutic regulatory T cells.
Milward K. et al, (2013), Transplantation, 95, 85 - 93
IL-1RII expressed by human regulatory T cells: a decoy strategy to ensure regulation
Hester J. and Wood KJ., (2012), IMMUNOLOGY, 137, 71 - 71
Low-dose rapamycin treatment increases the ability of human regulatory T cells to inhibit transplant arteriosclerosis in vivo.
Hester J. et al, (2012), Am J Transplant, 12, 2008 - 2016
Inflammatory Ly-6C(hi) monocytes play an important role in the development of severe transplant arteriosclerosis in hyperlipidemic recipients.
Schiopu A. et al, (2012), Atherosclerosis, 223, 291 - 298